[go: up one dir, main page]

CY1124478T1 - Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret - Google Patents

Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret

Info

Publication number
CY1124478T1
CY1124478T1 CY20211100784T CY211100784T CY1124478T1 CY 1124478 T1 CY1124478 T1 CY 1124478T1 CY 20211100784 T CY20211100784 T CY 20211100784T CY 211100784 T CY211100784 T CY 211100784T CY 1124478 T1 CY1124478 T1 CY 1124478T1
Authority
CY
Cyprus
Prior art keywords
kinase inhibitors
ret kinase
heterocyclic compounds
ret
compounds
Prior art date
Application number
CY20211100784T
Other languages
English (en)
Inventor
Allan Jordan
Rebecca NEWTON
Bohdan Waszkowycz
Silvia PAOLETTA
Euan Alexander Fraser Fordyce
George Hynd
Jonathan Mark Sutton
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of CY1124478T1 publication Critical patent/CY1124478T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ενώσεις του Τύπου Ι που λειτουργούν ως αναστολείς της δραστικότητας ενζύμου κινάσης RET (αναδιατεταγμένη κατά τη διάρκεια επιμόλυνσης): όπου οι δεσμοί το ΗΕΤ, δεσμοί a, b, c και d, τα Χ1, X2, X3, Χ4, R2 και R3 είναι καθένα όπως ορίζεται στο παρόν. Η παρούσα εφεύρεση αφορά επίσης διεργασίες για την παρασκευή αυτών των ενώσεων σε φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτές και τη χρήση τους στη θεραπεία πολλαπλασιαστικών διαταραχών, όπως καρίνος, όπως επίσης άλλων νόσων ή καταστάσεων στις οποίες εμπλέκεται η δραστικότητα κινάσης RET.
CY20211100784T 2016-04-15 2021-09-06 Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret CY1124478T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606631 2016-04-15
GB201619277 2016-11-14
PCT/GB2017/051076 WO2017178844A1 (en) 2016-04-15 2017-04-18 Heterocyclic compounds as ret kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1124478T1 true CY1124478T1 (el) 2022-07-22

Family

ID=58633035

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100784T CY1124478T1 (el) 2016-04-15 2021-09-06 Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret

Country Status (24)

Country Link
US (3) US10954241B2 (el)
EP (2) EP3442980B1 (el)
JP (3) JP6943876B2 (el)
KR (3) KR102390578B1 (el)
CN (2) CN115650985B (el)
AU (3) AU2017250448C1 (el)
BR (2) BR112018071097B1 (el)
CA (1) CA3020778A1 (el)
CY (1) CY1124478T1 (el)
DK (1) DK3442980T3 (el)
ES (1) ES2886587T3 (el)
HR (1) HRP20211362T1 (el)
HU (1) HUE056135T2 (el)
IL (3) IL289793B2 (el)
LT (1) LT3442980T (el)
MX (2) MX387394B (el)
PL (1) PL3442980T3 (el)
PT (1) PT3442980T (el)
RS (1) RS62322B1 (el)
RU (1) RU2742115C2 (el)
SG (2) SG10201911665UA (el)
SI (1) SI3442980T1 (el)
SM (1) SMT202100538T1 (el)
WO (1) WO2017178844A1 (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5832527B2 (ja) 2010-05-20 2015-12-16 アレイ バイオファーマ、インコーポレイテッド Ｔｒｋキナーゼ阻害剤としてのマクロ環化合物
HUE053067T2 (hu) 2015-07-16 2021-06-28 Array Biopharma Inc Helyettesített pirazolo[1,5-A]piridin vegyületek, mint RET kináz inhibitorok
TWI787018B (zh) 2015-11-02 2022-12-11 美商纜圖藥品公司 轉染過程重排之抑制劑
SMT202200348T1 (it) 2016-04-15 2022-11-18 Cancer Research Tech Ltd Composti eterociclici come inibitori della chinasi ret
AU2017250448C1 (en) 2016-04-15 2021-01-07 Cancer Research Technology Limited Heterocyclic compounds as RET kinase inhibitors
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
JP7061195B2 (ja) * 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
RS65127B1 (sr) 2018-04-03 2024-02-29 Blueprint Medicines Corp Ret inhibitor za primenu u lečenju kancera koji ima ret alteraciju
CA3092625A1 (en) * 2018-04-05 2019-10-10 Merck Patent Gmbh Heteroaryl compounds as type ii irak inhibitors and uses thereof
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
ES2976515T3 (es) 2018-10-05 2024-08-02 Annapurna Bio Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad del receptor APJ
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
US20220220104A1 (en) * 2019-04-03 2022-07-14 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory Pyrazolopyridine compound as ret inhibitor and application thereof
US20230312504A1 (en) * 2020-02-20 2023-10-05 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. Baiyunshan Pharmaceutical General Factory Quinoline compounds
CN115996929A (zh) * 2020-05-07 2023-04-21 阿道尔克斯治疗有限公司 腺苷A2a受体的拮抗剂
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
MX2023003995A (es) 2020-10-05 2023-06-12 Enliven Inc Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl.
TW202241419A (zh) * 2020-12-22 2022-11-01 美商基利科學股份有限公司 ６－取代之吲哚化合物
TWI838670B (zh) * 2020-12-22 2024-04-11 美商基利科學股份有限公司 經取代之吲哚化合物
MX2023012110A (es) 2021-04-16 2023-10-24 Gilead Sciences Inc Compuestos de tienopirrol.
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
TW202440078A (zh) 2021-09-10 2024-10-16 美商基利科學股份有限公司 噻吩并吡咯化合物
JP2024539641A (ja) 2021-10-15 2024-10-29 ステムライン セラピューティクス，インコーポレーテッド 癌の治療に使用するための変異ｒｅｔキナーゼの阻害剤
WO2024151519A2 (en) * 2023-01-09 2024-07-18 University Of Florida Research Foundatin, Incorporated Pparg modulators
KR20250023311A (ko) * 2023-08-09 2025-02-18 주식회사 대웅제약 신규한 화합물, 및 이를 포함하는 암 또는 종양의 예방 또는 치료용 약학적 조성물

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322779A3 (en) 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ATE248170T1 (de) * 1999-01-11 2003-09-15 Univ Princeton Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2006068760A2 (en) 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
SI1951724T1 (sl) * 2005-11-17 2011-09-30 Osi Pharmaceuticals Llc Kondenzirani biciklični mTOR inhibitorji
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
CN101389630A (zh) 2005-12-29 2009-03-18 艾博特公司 蛋白激酶抑制剂
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
PL2529622T3 (pl) 2006-09-22 2018-07-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
EP2178563A2 (en) * 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MY172151A (en) 2008-01-04 2019-11-14 Intellikine Llc Certain chemical entities, compositions and methods
WO2009114870A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
JP5788316B2 (ja) * 2008-07-08 2015-09-30 インテリカイン， エルエルシー キナーゼインヒビターおよび使用方法
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
EA036876B1 (ru) 2009-11-05 2020-12-30 Ризен Фармасьютикалз С.А. Ингибиторы pi3k киназы
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
WO2011094628A1 (en) 2010-01-28 2011-08-04 University Of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012006619A2 (en) 2010-07-09 2012-01-12 Northeastern University ANTIPARASITIC AGENTS BASED ON mTOR INHIBITORS
CN103491962B (zh) 2011-02-23 2016-10-12 因特利凯有限责任公司 激酶抑制剂的组合及其用途
WO2012151562A1 (en) 2011-05-04 2012-11-08 Intellikine, Llc Combination pharmaceutical compositions and uses thereof
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
AU2012341028C1 (en) * 2011-09-02 2017-10-19 Mount Sinai School Of Medicine Substituted pyrazolo[3,4-D]pyrimidines and uses thereof
JP6114296B2 (ja) 2011-11-08 2017-04-12 インテリカイン， エルエルシー 複数の医薬品を使用した治療レジメン
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
US20160272645A1 (en) 2013-10-18 2016-09-22 Medivation Technologies, Inc. Heterocyclic Compounds and Methods of Use
CA2922058A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
GB201321146D0 (en) * 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
US10221181B2 (en) 2014-11-14 2019-03-05 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
AU2016211630B2 (en) 2015-01-26 2021-03-25 University Of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
US10550124B2 (en) 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
EA201890730A1 (ru) * 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
US20190077856A1 (en) 2016-03-15 2019-03-14 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
SMT202200348T1 (it) * 2016-04-15 2022-11-18 Cancer Research Tech Ltd Composti eterociclici come inibitori della chinasi ret
AU2017250448C1 (en) * 2016-04-15 2021-01-07 Cancer Research Technology Limited Heterocyclic compounds as RET kinase inhibitors

Also Published As

Publication number Publication date
RS62322B1 (sr) 2021-10-29
ES2886587T3 (es) 2021-12-20
KR20240142568A (ko) 2024-09-30
IL289793B2 (en) 2023-03-01
BR112018071097B1 (pt) 2024-02-20
KR20220054894A (ko) 2022-05-03
PT3442980T (pt) 2021-09-13
BR112018071097A2 (pt) 2019-01-29
PL3442980T3 (pl) 2021-12-06
SI3442980T1 (sl) 2021-11-30
DK3442980T3 (da) 2021-08-30
BR122023026297A2 (pt) 2024-01-16
NZ747678A (en) 2024-05-31
CN109195972A (zh) 2019-01-11
EP3442980B1 (en) 2021-06-09
AU2020220079A1 (en) 2020-09-03
AU2017250448A1 (en) 2018-11-01
US20210155628A1 (en) 2021-05-27
JP2021193108A (ja) 2021-12-23
MX387394B (es) 2025-03-18
EP3960180A1 (en) 2022-03-02
RU2018138471A (ru) 2020-05-15
IL262185A (en) 2018-11-29
KR20180134983A (ko) 2018-12-19
HUE056135T2 (hu) 2022-01-28
AU2017250448B2 (en) 2020-05-21
CA3020778A1 (en) 2017-10-19
JP6943876B2 (ja) 2021-10-06
RU2742115C2 (ru) 2021-02-02
IL289793A (en) 2022-03-01
MX2021013110A (es) 2021-11-17
CN109195972B (zh) 2022-10-28
CN115650985A (zh) 2023-01-31
SG10201911665UA (en) 2020-01-30
WO2017178844A1 (en) 2017-10-19
CN115650985B (zh) 2024-08-02
RU2018138471A3 (el) 2020-05-15
US20230339954A1 (en) 2023-10-26
US11548896B2 (en) 2023-01-10
HRP20211362T1 (hr) 2021-11-26
AU2017250448C1 (en) 2021-01-07
IL262185B (en) 2022-02-01
MX2018012609A (es) 2019-08-01
KR102706837B1 (ko) 2024-09-19
SMT202100538T1 (it) 2021-11-12
SG11201808878UA (en) 2018-11-29
AU2022203916A1 (en) 2022-06-23
IL289793B (en) 2022-11-01
KR102390578B1 (ko) 2022-04-26
IL297192A (en) 2022-12-01
AU2020220079B2 (en) 2022-04-21
JP2023159230A (ja) 2023-10-31
JP2019515903A (ja) 2019-06-13
LT3442980T (lt) 2021-09-27
US10954241B2 (en) 2021-03-23
EP3442980A1 (en) 2019-02-20
US20190106425A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
CY1124478T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1123395T1 (el) Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
CY1122550T1 (el) Αρυλικες, ετεροαρυλικες και ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση των διαταραχων που διαμεσολαβουνται απο το συμπληρωμα
CY1124484T1 (el) 2-ετεροαρυλο-3-οξο-2,3-διυδροπυριδαζινο-4-καρβοξαμιδια για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1123025T1 (el) Αναστολεις βρωμοεπικρατειας
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1124680T1 (el) Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CY1126109T1 (el) Αναστολεις toy trpc6
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
CY1120836T1 (el) Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
MX391489B (es) Inhibidores heterociclicos de mct4.
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CY1123880T1 (el) Καινοτομοι 5-ητ2 ανταγωνιστες
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина